chlorpropamide (diabinese) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Chlorpropamide (DIABINESE®), is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. It appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide (DIABINESE®) lowers blood glucose during long-term administration has not been clearly established. Extra-pancreatic effects may play a part in the mechanism of action of oral sulfonylurea hypoglycemic drugs. While chlorpropamide is a sulfonamide derivative, it is devoid of antibacterial activity. Chlorpropamide (DIABINESE®) may also prove effective in controlling certain patients who have experienced primary or secondary failure to other sulfonylurea agent.   NCATS

Chemistry

  • SMILES: CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1
  • InChIKey: RKWGIWYCVPQPMF-UHFFFAOYSA-N
  • Mol. Mass: 276.74
  • ALogP: 1.74
  • ChEMBL Molecule:
    chlorpropamide  
More Chemistry

Pharmacology

Alternative names

1-(p-chlorobenzenesulfonyl)-3-propylurea | 1-(p-chlorophenylsulfonyl)-3-propylurea | 1-propyl-3-(p-chlorobenzenesulfonyl)urea | 4-chloro-n-((propylamino)carbonyl)benzenesulfonamide | 4-chloro-n-[(propylamino)carbonyl]benzenesulfonamide | chlorodiabina | chloronase | chloropropamide | chlorpropamid | chlorpropamide | chlorpropamidum | clorpropamida | diabemide | diabinese | diabineses | glucamide | glymese | melitase | n-(4-chlorophenylsulfonyl)-n'-propylurea | n-(p-chlorobenzenesulfonyl)-n'-propylurea | n-propyl-n'-(p-chlorobenzenesulfonyl)urea | n-propyl-n'-p-chlorophenylsulfonylcarbamide

Organizations (12)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (2)

Approved Indications (2)


 

Diabetes Insipidus

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (0)

Overview

  • Highest Phase: N/A
  • # of Trials: 1
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue